Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Determining the Optimal Site of Entry for Colloid Cyst Resection Using an Expandable Tubular Retractor in a Nondilated Ventricular System: Cadaveric Analysis and Illustrative Cases.

Operative neurosurgery (Hagerstown, Md.)·2026
Same author

Long-term changes in breast density reporting after implementation of BI-RADS 5<sup>th</sup> edition guidelines.

Journal of clinical imaging science·2026
Same author

Predictive capacity of mismatch repair status in the use of immune checkpoint inhibitors for the treatment of aggressive pituitary tumors and pituitary carcinomas: An illustrative case report and literature review.

Surgical neurology international·2026
Same author

Diffusing capacity of the lung for carbon monoxide, transfer coefficient of the lung for carbon monoxide and forced vital capacity/diffusing capacity of the lung for carbon monoxide in suspected systemic sclerosis-associated pulmonary hypertension: insights from the ASPIRE registry.

ERJ open research·2026
Same author

Co-designed principles for establishment of a virtual hospital.

Scientific reports·2026
Same author

Preferences of Pregnant Women and Healthcare Professionals on First-Trimester Ultrasound Screening for Fetal Anomalies: A Discrete Choice Experiment.

Prenatal diagnosis·2026

相关实验视频

Updated: May 7, 2026

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

新型炎症性肠病特定模型的风险调整性能.

Kellyn M Moran1, Sarah S Hellems2, Kiraat D Munshi1

  • 1Takeda Pharmaceuticals U.S.A., Inc., Cambridge, MA, USA.

Risk management and healthcare policy
|March 4, 2026
PubMed
概括

使用精算方法的新风险调整模型可以预测炎症性肠病 (IBD) 的成本. 这些模型是从索赔数据中开发的,它们显示了在管理IBD患者费用的现实实用性.

科学领域:

  • 卫生经济学 卫生经济学
  • 临床信息学 临床信息学
  • 胃肠病学 胃肠病学

背景情况:

  • 炎症性肠病 (IBD) 带来了相当大的医疗费用.
  • 准确的风险调整模型对于IBD管理中的资源配置和成本预测至关重要.
  • 现有的模型可能无法完全捕捉IBD相关支出的复杂性.

研究的目的:

  • 开发和评估新的精算风险调整模型,专门针对炎性肠病 (IBD).
  • 评估这些模型对同时和未来IBD相关成本的预测准确度.
  • 确定行政索赔数据在构建这些模型中的有用性.

主要方法:

  • 这是一项回顾性,横截面研究,利用了2020-2022年的行政索赔数据.
  • 基于IBD成本的克罗恩病和性结肠炎临床风险群的发展.
  • 应用线性回归模型来评估风险组和成本之间的关系,对保险类型和治疗使用进行单独分析.

主要成果:

  • 临床风险组解释了不同患者组的并发成本变异的不同百分比 (2.01%-20.99%).
  • 包括与IBD相关的住院治疗显著改善了并发成本预测 (R2高达41.56%).
  • 未来的模型显示了适度的预测能力,没有额外的预测因素提高了性能.
关键词:
精算方法是一种精算方法.有临床风险的群.炎症性肠病是一种炎症性肠病.风险调整风险的调整.

更多相关视频

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

相关实验视频

Last Updated: May 7, 2026

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

结论:

  • 成功开发了IBD患者的新型并发和前风险调整模型.
  • 这些模型有效地解释和预测使用行政索赔数据的IBD相关成本.
  • 开发的模型证明了IBD成本管理在各种医疗保健环境中的潜在现实实用性.